We have located links that may give you full text access.
Obesity and the absence of trochlear dysplasia increase the risk of revision in patellofemoral arthroplasty.
Knee 2016 March
PURPOSE: Proper indications and patient selection are of paramount importance in patellofemoral arthroplasty (PFA). Although factors predicting outcomes in total knee arthroplasty (TKA) have been studied, there are no such studies for modern PFA. This retrospective study reports the midterm clinical and radiological outcomes and survivorship of PFA, investigating the risk factors associated with poorer outcomes and higher revision rates.
METHODS: Fifty-one patients (51 knees) with isolated patellofemoral arthritis underwent PFA with a second-generation implant. The mean follow-up duration was 4.1 years (range, 2.2 to 6.1). The cohort was stratified into obese (body mass index (BMI)≥30 kg/m(2), n=16), overweight (BMI 25 to 29.9 kg/m(2), n=20) and control (BMI 18.5 to 24.9 kg/m(2), n=15) groups. The same cohort was stratified based on the presence (n=11) or absence (n=40) of trochlear dysplasia (TD).
RESULTS: The mean Knee Society objective and function scores, the Melbourne Knee score and the Physical Component Score of Short Form 36 improved significantly. Obesity was associated with no significant improvement in the Melbourne Knee score and the Knee Society function score (p>0.05), a higher incidence of radiographic outliers and lower patient satisfaction. There was no significant difference in outcomes between the TD and non-TD groups at two years (p>0.05), with a survivorship of 92.2%. Three revisions for progression of tibiofemoral osteoarthritis were noted in the non-TD and obese or overweight groups.
CONCLUSIONS: Patients with obesity and the absence of TD are at a potentially higher risk of revision surgery to TKA, and they should be counselled that PFA may represent a 'bridging' procedure.
LEVEL OF EVIDENCE: III.
METHODS: Fifty-one patients (51 knees) with isolated patellofemoral arthritis underwent PFA with a second-generation implant. The mean follow-up duration was 4.1 years (range, 2.2 to 6.1). The cohort was stratified into obese (body mass index (BMI)≥30 kg/m(2), n=16), overweight (BMI 25 to 29.9 kg/m(2), n=20) and control (BMI 18.5 to 24.9 kg/m(2), n=15) groups. The same cohort was stratified based on the presence (n=11) or absence (n=40) of trochlear dysplasia (TD).
RESULTS: The mean Knee Society objective and function scores, the Melbourne Knee score and the Physical Component Score of Short Form 36 improved significantly. Obesity was associated with no significant improvement in the Melbourne Knee score and the Knee Society function score (p>0.05), a higher incidence of radiographic outliers and lower patient satisfaction. There was no significant difference in outcomes between the TD and non-TD groups at two years (p>0.05), with a survivorship of 92.2%. Three revisions for progression of tibiofemoral osteoarthritis were noted in the non-TD and obese or overweight groups.
CONCLUSIONS: Patients with obesity and the absence of TD are at a potentially higher risk of revision surgery to TKA, and they should be counselled that PFA may represent a 'bridging' procedure.
LEVEL OF EVIDENCE: III.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app